Walter A. Gilbert
Vorsitzender bei Prolexys Pharmaceuticals, Inc.
Profil
Walter Gilbert, PhD, joined BioVentures Investors in 2003, after being an outside advisor to the firm since its inception, and is currently a Venture Partner.
He is a leading molecular biologist, and was the Carl M.
Loeb University Professor at Harvard University.
In 1975, Wally developed a method of rapid DNA sequencing for which he received the Nobel Prize in Chemistry in 1980.
Wally was a founder of Biogen, and served as Chairman and CEO until 1985.
While a member of the BioVentures Investors Fund I Board of Advisors, he co-founded Pintex Pharmaceuticals Inc., a Fund I portfolio company, and served as Chairman of the Board of Directors.
Formerly, he was a co-founder and Vice-Chairman of Myriad Genetics Inc. (NASDAQ: MYGN) and a co-founder and Chairman of Paratek Pharmaceuticals Inc. Wally was also a co-founder and Director of Memory Pharmaceuticals Inc., which was acquired by Roche, and served as a Director of Transkaryotic Therapies, which now goes by the name Shire Human Genetic Therapies.
Wally holds an AB in Chemistry and Physics from Harvard College, an MA in Physics from Harvard University, and a PhD in Mathematics from Cambridge University.
He has multiple honorary doctorates.
Aktive Positionen von Walter A. Gilbert
| Unternehmen | Position | Beginn |
|---|---|---|
BioVentures Investors
 BioVentures Investors Investment ManagersFinance BioVentures Investors (BioVentures) is a venture capital firm founded in 1997 by Peter J. Feinstein and Marc E. Goldberg. The firm is headquartered in Wellesley, Massachusetts. | Private Equity Investor | 01.01.2001 |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Vorsitzender | - |
ActivBiotics, Inc.
 ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.1985 |
National Academy of Sciences
 National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | 01.01.1976 |
Ehemalige bekannte Positionen von Walter A. Gilbert
| Unternehmen | Position | Ende |
|---|---|---|
| MYRIAD GENETICS, INC. | Gründer | 04.12.2020 |
| PARATEK PHARMACEUTICALS, INC. | Gründer | 01.01.2014 |
Memory Pharmaceuticals Corp.
 Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Gründer | 06.01.2009 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Vorstandsvorsitzender | 01.01.1985 |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Walter A. Gilbert
| University of Cambridge | Doctorate Degree |
| Harvard University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Health Technology |
NetGenics, Inc.
 NetGenics, Inc. Packaged SoftwareTechnology Services NetGenics, Inc. develops software solutions for life science research. The firm provides bioinformatics solutions including the use of information technology by life science research companies to convert massive amounts of data into useful information that their scientists can then use in the development of new drugs, gene therapies, and agricultural products. The company was founded in 1996 and is headquartered in Cleveland, OH. | Technology Services |
BioVentures Investors
BioVentures Investors Investment ManagersFinance BioVentures Investors (BioVentures) is a venture capital firm founded in 1997 by Peter J. Feinstein and Marc E. Goldberg. The firm is headquartered in Wellesley, Massachusetts. | Finance |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Health Technology |
Pintex Pharmaceuticals, Inc.
 Pintex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pintex Pharmaceuticals, Inc. used to discover and develop cancer therapeutics. The company used to discover and commercialize new antibiotics focused on drug resistance. Pintex Pharmaceuticals was founded by Walter Gilbert, Kung Ping Lu and Janusz Sowadski in 1999 and was headquartered in Watertown, MA. | Health Technology |
Cylene Pharmaceuticals, Inc.
 Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Health Technology |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
